Determination of Multisystem Inflammatory Syndrome with COVID-19 in Children
Published: 2023-07-03
Page: 90-93
Issue: 2023 - Volume 6 [Issue 1]
Are Anusha
Department of Pharmacy Practice, St. Pauls College of Pharmacy, Hyderabad, India.
Manda Anusha *
Department of Pharmacy Practice, St. Pauls College of Pharmacy, Hyderabad, India.
*Author to whom correspondence should be addressed.
Abstract
Multisystem inflammatory syndrome in children is caused by the SARS-CoV-2. MISC varies from Mild to Severe. Most of the children do not exhibit appropriate symptoms. MISC effects respiratory system, Gastrointestinal system, and cardiocirculatory system. MISC is treated with symptomatic treatment. No child till now had any mortality. In this case report a female child of 10years was diagnosed with MISC. Her CBP varied from day to day with pancytopenia. The child IgM was positive for Covid 19. The child experienced the symptoms of fever, seizures and syncope. She was treated with Antibiotics and symptomatic treatment.
Keywords: SARS-CoV-2, multi inflammatory syndrome in children, IgM
How to Cite
References
Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis.
Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China [published online ahead of print, 2020 Mar 13].
Ludvigsson JF. Systematic review of COVID‐19 in children shows milder cases and a better prognosis than adults.
Harwood R, Allin B, Jones CE, Whittaker E, Ramnarayan P, Ramanan AV, et al. A national consensus management pathway for pediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): Results of a national Delphi process. Lancet Child Adolesc Health. 2021;5(2):133–41.
Hoste L, Van Paemel R, Haerynck F. Multisystem inflammatory syndrome in children related to COVID-19: a systematic review. Eur J Pediatr. 2021;180(7):2019–34.
Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020;395(10237):1607–8
Levin M. Childhood multisystem inflammatory syndrome - a new challenge in the pandemic. N Engl J of Med. 2020;383(4):393–5.
Radia T, Williams N, Agrawal P, Harman K, Weale J, Cook J, et al. Multi-system inflammatory syndrome in children & adolescents (MIS-C): A systematic review of clinical features and presentation. Paediatr Respir Rev. 2021;38:51–7.
Dolinger MT, Person H, Smith R, Jarchin L, Pittman N, Dubinsky MC, Lai J. Pediatric Crohn's disease and multisystem inflammatory syndrome in children (MIS-C) and COVID-19 treated with infliximab. Journal of pediatric gastroenterology and Nutrition; 2020 May 5.
Cheng MH, Zhang S, Porritt RA, Arditi M, Bahar I. An insertion is unique to SARS-CoV-2 exhibits a superantigenic character strengthened by recent mutations. Biorxiv; 2020 May 21.
Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D, Oltolini C, Castiglioni B, Din CT, Boffini N, Tomelleri A. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: A retrospective cohort study. The Lancet Rheumatology. 2020;2(6):e325-31.
Miller J, Cantor A, Zachariah P, Ahn D, Martinez M, Margolis KG. Gastrointestinal symptoms as a major presentation component of a novel multisystem inflammatory syndrome in children that is related to coronavirus disease 2019: A single center experience of 44 cases. Gastroenterology. 2020; 159(4):1571-4.
Greene Andrea G, Mona S, Eric R, Richard S. Toxic shock-like syndrome and COVID-19: Multisystem inflammatory syndrome in children (MIS-C). The American Journal of Emergency Medicine. 2020;11.